Navigation Links
EORTC BOS 2 trial opens for patients with resectable liver metastases from colorectal cancer
Date:6/4/2013

Colorectal cancer (CRC) is the second most frequent cause of cancer-related mortality in both Europe and the United States. Treatment for patients with resectable hepatic metastases from colorectal cancer consists of surgery combined with chemotherapy, but recurrence is observed in two thirds of these patients. In order to improve the outcome for these patients, EORTC trial 40091 BOS 2 will test the efficacy of adding bevacizumab or panitumumab to the standard treatment, peri-operative FOLFOX 4 chemotherapy.

Bevacizumab is a monoclonal antibody which targets the vascular endothelial growth factor (VEGF), and blocking VEGF could deprive the cancer of required nutrients. Panitumumab targets the epidermal growth factor receptor (EGFR). EGFR gene expression is upregulated in approximately 60 to 80% of CRC cases, and this has been linked to poor survival.

Dr. Bernard Nordlinger, CHU Ambroise Pare AP-HP, Boulogne-Billancourt and Coordinator of this study, says "The objective of this trial is to determine a new standard of care for these patients." The randomized phase 2 EORTC trial will investigate if treatment with perioperative modified FOLFOX6 plus either bevacizumab or panitumumab improves progression-free survival and pathological response in patients with up to eight resectable liver metastases resulting from wild type KRAS CRC as compared to treatment with perioperative modified FOLFOX 6 alone.

Dr. Stephane Benoist, Assistance Publique, Hpitaux de Paris, Hopital De Bicetre AP-HP, Le Kremlin Bicetre and co-Coordinator of this study, says "Following the EPOC study, perioperative FOLFOX chemotherapy became the new standard of care in many countries for patients with resectable colorectal liver metastases. Nevertheless, most patients developed recurrence despite perioperative FOLFOX chemotherapy. One of the ways to improve long term prognosis is to intensify the perioperative chemotherapy. The BOS 2 study addresses a major clinical ques
'/>"/>

Contact: John Bean
john.bean@eortc.be
European Organisation for Research and Treatment of Cancer
Source:Eurekalert

Page: 1 2

Related medicine news :

1. EORTC study shows radiotherapy and surgery provide regional control for breast cancer patients
2. Markers in Cancer, a joint meeting by ASCO, EORTC & NCI, 7-9 Nov 2013 (diagnostic tutorial on 5-7)
3. EORTC study identifies patients with anaplastic oligodendroglioma that benefit from adjuvant PCV
4. EORTC led intergroup trial investigates Imatinib failure-free survival in patients with GIST
5. Media alert: 24th EORTC - NCI - AACR Symposium Molecular Targets and Cancer Therapeutics
6. New Hepatitis C Clinical Trial Now Enrolling at Avail Clinical Research near Orlando, Florida; Accepting M/F Patients with Hep C Age 18-65
7. Low Back Pain Clinical Trial Now Enrolling at Achieve Clinical Research in Birmingham, Alabama; Accepting M/F Patients with Chronic Low Back Pain Age 18-80
8. DePuy ASR Hip Implant Lawyers at Wright & Schulte LLC Pleased with Judge’s Decision to Uphold $8.3 Million Award in California DePuy ASR Hip Lawsuit Trial
9. True-Dose Pets Launches New Trial-Sized Product Line
10. Vaginal Mesh Lawsuits Move Forward, as Bernstein Liebhard LLP Notes New Pretrial Order in Federal Transvaginal Mesh Litigation
11. CureLauncher Introduces Personalized Clinical Trial Matching Service
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... May 22, 2015 The American College ... events in June. They will hold a webinar on ... a two-day class on Classical Chinese Medicine. , Webinar ... Dr. Steve Given, the Dean of Clinical Education, will ... new First Professional Doctorate program. ACTCM is currently developing ...
(Date:5/22/2015)... East Liverpool, OH (PRWEB) May 22, 2015 ... today announced that Kyle Johnson, the health system’s Chief ... pursue other interests. Johnson has served as the company ... announced Wesley West will be joining the health system ... operations on an interim basis, while the Board of ...
(Date:5/22/2015)... Halifax, NS (PRWEB) May 22, 2015 ... into a sale agreement with US-based health brand Nature’s ... Ascenta Skin brand. Retention of Ascenta Skin is an ... St-Onge is excited about this opportunity to further develop ... industry. , Ascenta Skin is a breakthrough, anti-aging ...
(Date:5/22/2015)... (PRWEB) May 22, 2015 Combination ... treatment option for chronic obstructive pulmonary disorder (COPD) ... plc and AstraZeneca plc as well as Germany’s ... share and position. But will market payers, clinicians ... already well-entrenched products to completely new ones? , ...
(Date:5/22/2015)... (PRWEB) May 22, 2015 “It’s ... MS/CCC, SLP, RAC-CT, CHHRP-QT, Vice President of Clinical ... very important ‘language’ that impacts how care is ... leader in long term care reimbursement, operations and ... programs and talent management, launches a new series ...
Breaking Medicine News(10 mins):Health News:ACTCM Announces Upcoming June Events 2Health News:River Valley Health Partners Announces CFO Transition, Appointment of Interim CFO 2Health News:Ascenta Skin President Announces Plans to Grow Brand 2Health News:Chronic Obstructive Pulmonary Disorder Therapeutics Market Discussed in In-demand FirstWord Report Published at MarketPublishers.com 2Health News:Harmony Healthcare International Takes the Lead in Launching ICD-10 Coding Transition in Post-Acute Care 2Health News:Harmony Healthcare International Takes the Lead in Launching ICD-10 Coding Transition in Post-Acute Care 3
... of Cincinnati (UC) researcher will receive $2.5 million over ... (NIDA) to support his work on a potential immunotherapy ... in the psychiatry and behavioral neuroscience department, is one ... Awards for Innovative Medication Development Research. Award winners receive ...
... targeted therapies can reduce tumors rapidly. However, not all ... do often develop resistance over time. Looking for a ... Fox Chase Cancer Center hypothesized that hitting already weakened ... thembut only if it was the right second agent. ...
... be improved with training and the improvement is marked ... University study. A research team led by ... of the brain that controls impulsive behavior and the ... findings could have a significant impact on the diagnosis ...
... By Steven Reinberg HealthDay Reporter , ... finds it,s safe to take the blood thinner Plavix ... that said the combination compromised Plavix,s effectiveness. "We ... and proton-pump inhibitors," said lead researcher Dr. Mette Charlot ...
... tenth anniversary of the Jackson Heart Study (JHS) will ... JHS is the largest study in history to investigate ... lung disease, stroke, diabetes, and other important diseases in ... among African-Americans than among whites in the United States. ...
... CHAPEL HILL, N.C. Scientists from University of North Carolina ... Inc. announced today findings from a large clinical study ... the worsening of osteoarthritis. The study, which was ... with X-ray evidence of knee osteoarthritis who inherited a ...
Cached Medicine News:Health News:Researcher wins $2.5 million award from National Institute on Drug Abuse 2Health News:'Synthetic lethality' strategy improves molecularly targeted cancer therapy 2Health News:'Synthetic lethality' strategy improves molecularly targeted cancer therapy 3Health News:Queen's University researchers locate impulse control center in brain 2Health News:Plavix, Heartburn Drug Safe to Take Together: Study 2Health News:NIH celebrates 10 years of research into health disparities 2Health News:UNC researchers identify genetic patterns that may predict osteoarthritis 2Health News:UNC researchers identify genetic patterns that may predict osteoarthritis 3
(Date:5/22/2015)... 2015  In a sweeping analysis assessing the current ... Exchange researchers conclude that there remains considerable room ... all age groups, but especially for adolescents and young ... diabetes treatment, underscoring the need to address barriers to ... help type 1 patients achieve optimal metabolic control. ...
(Date:5/22/2015)... 22, 2015  China Nepstar Chain Drugstore Ltd. (NYSE: ... drugstore chain in China based ... the resignation of Mr. Fuxiang Zhang as ... immediately. Ms. Rebecca Yingnan Zhang has been ... of directors, effective immediately. Meanwhile, Ms. Zhang resigned from ...
(Date:5/21/2015)... DUBLIN , May 21, 2015 ... has announced the addition of the "North ... & Graft), by Application (Surgical Wound, & Ulcer), ... Forecast to 2019" report to their offering. ... wound care market is estimated to grow at ...
Breaking Medicine Technology:Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 2Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 3Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 4Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 5China Nepstar Chain Drugstore Ltd. Announces Management Change and New Director Appointment 2China Nepstar Chain Drugstore Ltd. Announces Management Change and New Director Appointment 3North American Active Wound Care Market 2015-2019 with Smith and Nephew, Molyncke HealthCare & ConvaTec Dominating 2
... Inc. and the GSK Clinical Imaging Centre (part of the GlaxoSmithKline Group ... antibody asset currently under development by GSK in the field of oncology. ... "ImaginAb is pleased to ... Behrenbruch , CEO of ImaginAb. "Not only does GSK have an excellent ...
... , SOUTH SAN FRANCISCO, Calif. , May ... from 32 prospective studies was published in The ... data shows that elevated levels of lipoprotein-associated phospholipase A2 ... increased risk of coronary heart disease similar in magnitude ...
Cached Medicine Technology:ImaginAb, Inc. and GlaxoSmithKline Establish Collaboration 2Large Meta-Analysis Further Validates Benefit of Measuring Lp-PLA2 for Coronary Heart Disease and Ischemic Stroke Risk Assessment 2Large Meta-Analysis Further Validates Benefit of Measuring Lp-PLA2 for Coronary Heart Disease and Ischemic Stroke Risk Assessment 3
... respiration and ventilation., ,The Capnomac Ultima is ... monitors available. The Capnomac Ultima is available in ... measure the essential airway gas parameters, CO 2 ... O easily and reliability. The Capnomac Ultima also ...
Adhesive discs sold on rolls of 100, 250, or 1000 each. Manufactured from non-latex medical grade adhesives & material. One size fits all chest pieces....
For accurately monitoring core temperature and heart and breath sounds as well as for gastric suctioning....
For accurately monitoring core temperature and heart and breath sounds....
Medicine Products: